{
  "url": "https://openlegislation.uk/council-of-the-pharmaceutical-society-of-northern-ireland-continuing-professional-development-regulations-northern-ireland-2012/regulation-6",
  "json_url": "https://openlegislation.uk/council-of-the-pharmaceutical-society-of-northern-ireland-continuing-professional-development-regulations-northern-ireland-2012/regulation-6.json",
  "legislation": "nisr/2012/312",
  "legislation_title": "The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) Regulations (Northern Ireland) 2012",
  "legislation_url": "https://openlegislation.uk/council-of-the-pharmaceutical-society-of-northern-ireland-continuing-professional-development-regulations-northern-ireland-2012",
  "path": "regulation/6",
  "kind": "regulation",
  "number": "6",
  "heading": "Subsequent action by the registrar: stage 2",
  "text": "(1) Where—\n(a) the registrar has served a Notice of Intention to Remove on a registered person; and\n(b) has not received any representations from the registered person within the 28 day period referred to in that notice (see regulation 5(5)(d)... and (g)),\nthe registrar may remove the name of the registered person, or the annotation recorded against the registered person's name in respect of a specialist area of practice, from the register.\n(2) The following paragraphs apply where the registrar has received representations from the registered person within the 28 day period referred to in the Notice of Intention to Remove.\n(3) The registrar—\n(a) must consider the representations and any evidence received; and\n(b) may make such further inquiries (including obtaining legal advice) as the registrar considers necessary or expedient.\n(4) The registrar must close the matter and notify the registered person accordingly where the registrar is satisfied that the registered person did not—\n(a) fail to comply with the requirements or conditions of the CPD framework; or\n(b) make a false declaration about compliance with the requirements or conditions of the CPD framework.\n(5) Where the registrar is not so satisfied and, in making a determination, proposes to rely on evidence that was obtained as a result of the registrar's further inquiries under paragraph (3)(b), the registrar must send to the registered person—\n(a) copies of that evidence (in a form that can be copied); and\n(b) ... a notice (referred to in these Regulations as a “supplementary notice”) which—\n(i) invites the registered person to submit written representations, and any relevant additional evidence, to the registrar as to why the name of the registered person or the annotation recorded against the registered person's name should not be removed from the register, and\n(ii) informs the registered person that any such representations or evidence must be submitted no later than 28 days after service of the supplementary notice .\n(iii) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n(iv) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n(6) Paragraphs (3) to (5) also have effect in relation to any further representations from the registered person which the registrar receives within the 28 day period referred to in a supplementary notice.\n(7) Unless the registrar determines the matter in accordance with paragraph (4), the registrar must proceed to determine it under regulation 7—\n(a) in any case where paragraph (5) does not apply; or\n(b) if that paragraph does apply, once the requirements of paragraphs (5) and (6) have been fully complied with.",
  "extent": "N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Words in reg. 6(1)(b) omitted (31.5.2013) by virtue of The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) (Amendment) Regulations (Northern Ireland) 2013 (S.R. 2013/147), regs. 1(1), 4(a)"
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Words in reg. 6(5)(b) omitted (31.5.2013) by virtue of The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) (Amendment) Regulations (Northern Ireland) 2013 (S.R. 2013/147), regs. 1(1), 4(b)(i)"
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Word in reg. 6(5)(b)(i) inserted (31.5.2013) by The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) (Amendment) Regulations (Northern Ireland) 2013 (S.R. 2013/147), regs. 1(1), 4(b)(ii)"
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Reg. 6(5)(b)(ii): full stop substituted for semicolon (31.5.2013) by The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) (Amendment) Regulations (Northern Ireland) 2013 (S.R. 2013/147), regs. 1(1), 4(b)(iii)"
    },
    {
      "type": "F",
      "label": "F5",
      "text": "Reg. 6(5)(b)(iii)(iv) omitted (31.5.2013) by virtue of The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) (Amendment) Regulations (Northern Ireland) 2013 (S.R. 2013/147), regs. 1(1), 4(b)(iv)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/nisr/2012/312/regulation/6",
    "retrieved_at": "2026-10-29T01:14:23.545536+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}